Magnetic resonance imaging for characterization of hepatocellular carcinoma metabolism

With a better understanding of the pathophysiological and metabolic changes in hepatocellular carcinoma (HCC), multiparametric and novel functional magnetic resonance (MR) and positron emission tomography (PET) techniques have received wide interest and are increasingly being applied in preclinical and clinical research. These techniques not only allow for non-invasive detection of structural, functional, and metabolic changes in malignant tumor cells but also characterize the tumor microenvironment (TME) and the interactions of malignant tumor cells with the TME, which has hypoxia and low pH, resulting from the Warburg effect and accumulation of metabolites produced by tumor cells and other cellular components. The heterogeneity and complexity of the TME require a combination of images with various parameters and modalities to characterize tumors and guide therapy. This review focuses on the value of multiparametric magnetic resonance imaging and PET/MR in evaluating the structural and functional changes of HCC and in detecting metabolites formed owing to HCC and the TME.

[1]  Zhuoyue Tang,et al.  Proton Magnetic Resonance Spectroscopy at 3.0T in Rabbit With VX2 Liver Cancer: Diagnostic Efficacy and Correlations With Tumor Size , 2022, Frontiers in Oncology.

[2]  Yikai Xu,et al.  Evaluation of microvascular invasion of hepatocellular carcinoma using whole-lesion histogram analysis with the stretched-exponential diffusion model. , 2021, The British journal of radiology.

[3]  Xiao-Ming Zhang,et al.  A study of the correlations between IVIM-DWI parameters and the histologic differentiation of hepatocellular carcinoma , 2021, Scientific Reports.

[4]  R. Grimm,et al.  Magnetic resonance imaging and diffusion-weighted imaging-based histogram analyses in predicting glypican 3-positive hepatocellular carcinoma. , 2021, European journal of radiology.

[5]  Takanori Ito,et al.  Prediction of Hepatocellular Carcinoma by Liver Stiffness Measurements Using Magnetic Resonance Elastography After Eradicating Hepatitis C Virus , 2021, Clinical and translational gastroenterology.

[6]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[7]  R. Wu,et al.  Noninvasive Detection of Extracellular pH in Human Benign and Malignant Liver Tumors Using CEST MRI , 2020, Frontiers in Oncology.

[8]  B. Taouli,et al.  Assessment of Hepatocellular Carcinoma Response to 90Y Radioembolization Using Dynamic Contrast Material-enhanced MRI and Intravoxel Incoherent Motion Diffusion-weighted Imaging. , 2020, Radiology. Imaging cancer.

[9]  J. Duncan,et al.  Extracellular pH mapping of liver cancer on a clinical 3T MRI scanner , 2020, Magnetic resonance in medicine.

[10]  Y. Jeong,et al.  Metabolic Alterations Associated with Early-Stage Hepatocellular Carcinoma and Their Correlation with Aging and Enzymatic Activity in Patients with Viral Hepatitis-Induced Liver Cirrhosis: A Preliminary Study , 2020, Journal of clinical medicine.

[11]  G. Cabibbo,et al.  Hyperintense nodule-in-nodule on hepatobiliary phase arising within hypovascular hypointense nodule: Outcome and rate of hypervascular transformation. , 2019, European journal of radiology.

[12]  Hai-Feng Liu,et al.  Whole-lesion histogram analysis metrics of the apparent diffusion coefficient: a correlation study with histological grade of hepatocellular carcinoma , 2019, Abdominal Radiology.

[13]  B. V. Van Beers,et al.  Assessing Tumor Mechanics by MR Elastography at Different Strain Levels , 2019, Journal of magnetic resonance imaging : JMRI.

[14]  M. Miquel,et al.  Improving liver lesion characterisation using retrospective fusion of FDG PET/CT and MRI. , 2019, Clinical imaging.

[15]  P. V. van Diest,et al.  Early detection of changes in phospholipid metabolism during neoadjuvant chemotherapy in breast cancer patients using phosphorus magnetic resonance spectroscopy at 7T , 2019, NMR in biomedicine.

[16]  S. Venkatesh,et al.  Hepatocellular Carcinoma: State of the Art Imaging and Recent Advances , 2019, Journal of clinical and translational hepatology.

[17]  Wei Huang,et al.  Multiparametric FDG-PET/MRI of Hepatocellular Carcinoma: Initial Experience , 2018, Contrast media & molecular imaging.

[18]  R. Ehman,et al.  3D MR Elastography of Hepatocellular Carcinomas as a Potential Biomarker for Predicting Tumor Recurrence , 2018, Journal of magnetic resonance imaging : JMRI.

[19]  O. Matsui,et al.  Peri-tumoral hyperintensity on hepatobiliary phase of gadoxetic acid-enhanced MRI in hepatocellular carcinomas: correlation with peri-tumoral hyperplasia and its pathological features , 2018, Abdominal Radiology.

[20]  Jimmy D Bell,et al.  Reference range of liver corrected T1 values in a population at low risk for fatty liver disease—a UK Biobank sub-study, with an appendix of interesting cases , 2018, Abdominal Radiology.

[21]  Q. Ye,et al.  T1 mapping on gadoxetic acid-enhanced MR imaging predicts recurrence of hepatocellular carcinoma after hepatectomy. , 2018, European journal of radiology.

[22]  Fang Yuan,et al.  Glucose as a stimulation agent in the BOLD functional magnetic resonance imaging for liver cirrhosis and hepatocellular carcinoma: a feasibility study , 2018, Abdominal Radiology.

[23]  Lunan Yan,et al.  Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: A meta‐analysis , 2017, Hepatology.

[24]  B. Song,et al.  T1 mapping combined with Gd-EOB-DTPA-enhanced magnetic resonance imaging in predicting the pathologic grading of hepatocellular carcinoma. , 2017, Journal of biological regulators and homeostatic agents.

[25]  M. Viergever,et al.  Preoperative indication for systemic therapy extended to patients with early-stage breast cancer using multiparametric 7-tesla breast MRI , 2017, PloS one.

[26]  M. Forsting,et al.  18 F-FDG PET/MR imaging in patients with suspected liver lesions: Value of liver-specific contrast agent Gadobenate dimeglumine , 2017, PloS one.

[27]  I. Cho,et al.  Quantitative assessment of simultaneous F-18 FDG PET/MRI in patients with various types of hepatic tumors: Correlation between glucose metabolism and apparent diffusion coefficient , 2017, PloS one.

[28]  S. Shiraishi,et al.  Measuring hepatic functional reserve using T1 mapping of Gd-EOB-DTPA enhanced 3T MR imaging: A preliminary study comparing with 99mTc GSA scintigraphy and signal intensity based parameters. , 2017, European journal of radiology.

[29]  J. Han,et al.  Value of MR elastography for the preoperative estimation of liver regeneration capacity in patients with hepatocellular carcinoma , 2017, Journal of magnetic resonance imaging : JMRI.

[30]  R. Wu,et al.  Extracellular pH is a biomarker enabling detection of breast cancer and liver cancer using CEST MRI , 2017, Oncotarget.

[31]  Jeong Min Lee,et al.  Hepatic stiffness measurement by using MR elastography: prognostic values after hepatic resection for hepatocellular carcinoma , 2017, European Radiology.

[32]  B. Taouli,et al.  Value of tumor stiffness measured with MR elastography for assessment of response of hepatocellular carcinoma to locoregional therapy , 2017, Abdominal Radiology.

[33]  Ellen Ackerstaff,et al.  Characterization of the Tumor Microenvironment and Tumor–Stroma Interaction by Non-invasive Preclinical Imaging , 2017, Front. Oncol..

[34]  K. Sugimoto,et al.  3D analysis of apparent diffusion coefficient histograms in hepatocellular carcinoma: correlation with histological grade , 2017, Cancer Imaging.

[35]  Xinming Zhao,et al.  Diagnostic value of 3.0T 1H MRS with choline-containing compounds ratio (∆CCC) in primary malignant hepatic tumors , 2016, Cancer Imaging.

[36]  Matthew D. Robson,et al.  Multiparametric magnetic resonance imaging predicts clinical outcomes in patients with chronic liver disease , 2016, Journal of hepatology.

[37]  Yuehua Li,et al.  1H Magnetic Resonance Spectroscopy Predicts Hepatocellular Carcinoma in a Subset of Patients With Liver Cirrhosis , 2015, Medicine.

[38]  J. Gore,et al.  Noninvasive Measurements of Glycogen in Perfused Mouse Livers Using Chemical Exchange Saturation Transfer NMR and Comparison to 13C NMR Spectroscopy , 2015, Analytical chemistry.

[39]  Masakazu Yamamoto,et al.  Gd‐EOB‐DTPA‐enhanced magnetic resonance imaging and alpha‐fetoprotein predict prognosis of early‐stage hepatocellular carcinoma , 2014, Hepatology.

[40]  M. A. van den Bosch,et al.  Detection of alterations in membrane metabolism during neoadjuvant chemotherapy in patients with breast cancer using phosphorus magnetic resonance spectroscopy at 7 Tesla , 2014, SpringerPlus.

[41]  M. Robson,et al.  Multiparametric magnetic resonance for the non-invasive diagnosis of liver disease , 2014, Journal of hepatology.

[42]  S. Friedman,et al.  Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. , 2013, Gastroenterology.

[43]  L. Roberts,et al.  The tumor microenvironment in hepatocellular carcinoma: current status and therapeutic targets. , 2011, Seminars in cancer biology.

[44]  S. Dymarkowski,et al.  Diffusion-weighted MRI provides additional value to conventional dynamic contrast-enhanced MRI for detection of hepatocellular carcinoma , 2009, European Radiology.

[45]  F. Gallagher,et al.  13C MR spectroscopy measurements of glutaminase activity in human hepatocellular carcinoma cells using hyperpolarized 13C‐labeled glutamine , 2008, Magnetic resonance in medicine.

[46]  J. Lee,et al.  Different glucose uptake and glycolytic mechanisms between hepatocellular carcinoma and intrahepatic mass-forming cholangiocarcinoma with increased (18)F-FDG uptake. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[47]  M. Gruwel,et al.  Monitoring the development of hepatocellular carcinoma in woodchucks using 31P-MRS , 2005, Magnetic Resonance Materials in Physics, Biology and Medicine.

[48]  J. Bruix,et al.  Focus on hepatocellular carcinoma. , 2004, Cancer cell.

[49]  T. Saga,et al.  Relationship between retention index in dual-phase (18)F-FDG PET, and hexokinase-II and glucose transporter-1 expression in pancreatic cancer. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[50]  R J Maxwell,et al.  Effect of changing tumor oxygenation on glycolytic metabolism in a murine C3H mammary carcinoma assessed by in vivo nuclear magnetic resonance spectroscopy. , 2001, Cancer research.

[51]  W. Negendank,et al.  Studies of human tumors by MRS: A review , 1992, NMR in biomedicine.

[52]  M. Weiner,et al.  Hepatic cancers and their response to chemoembolization therapy. Quantitative image-guided 31P magnetic resonance spectroscopy. , 1992, Investigative radiology.

[53]  Jimmy D Bell,et al.  In vivo and in vitro 31P magnetic resonance spectroscopy of focal hepatic malignancies , 1992, NMR in biomedicine.

[54]  O. Warburg,et al.  The Metabolism of Carcinoma Cells , 1925 .

[55]  U. Motosugi,et al.  Liver stiffness measured by magnetic resonance elastography as a risk factor for hepatocellular carcinoma: a preliminary case–control study , 2012, European Radiology.

[56]  E. Negelein,et al.  THE METABOLISM OF CARCINOMA CELLS , 2011 .

[57]  H. Tonami,et al.  FDG PET measurement of the proliferative potential of non-small cell lung cancer. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.